Рациональная муколитическая терапия кашля у детей
DOI:
https://doi.org/10.15574/SP.2016.77.47Ключевые слова:
кашель, дети, лечениеАннотация
В обзорной статье показаны современные представления об основных причинах формирования и этиопатогенетических подходах к лечению кашля у детей; описано действие лекарственных препаратов, применяемых в детской практике.
Ключевые слова: кашель, дети, лечение.
Библиографические ссылки
Volosovets AP. 2009. Sovremennyie podhodyi k lecheniyu ostrogo bronhita u detey. Zdorov'ya Ukrayini. 4/1: 26—27.
Duka ED, Efanova AA. 2007. Sovremennyie podhodyi k simptomaticheskoy terapii ostryih zabolevaniy organov dyihaniya u detey. Novosti meditsinyi i farmatsii. 4(208). http://www.mif-ua.com/archive/article/3266.
Shpeko NI, Beketova HV, Mustak Mokhammed Ali, Hnatenko TM. 2014. Efektyvnist i bezpeka kombinovanykh mukoaktyvnykh vidkharkuvalnykh zasobiv pry hostrykh repiratornykh infektsiiakh u ditei. Zb nauk pr spivrobit NMAPO imeni PL Shupyka. 23(3): 389—395.
Kotlukov VK, Kazyukova TV. 2011. Differentsirovannyiy podhod k terapii kashlya u detey. Pediatriya. 90; 2.
Kramarev SA. 2013. Differentsirovannyiy podhod k lecheniyu kashlya. Zdorove rebenka. 6(49). http://www.mif-ua.com/archive/article/37095.
Maydannik VG. 2006. Effektivnost primeneniya preparata «Milistan ot kashlya» pri ostryih bronhitah u detey (4 faza klinicheskih issledovaniy). Zdorove rebenka. 3(3). http://www.mif-ua.com/archive/article/857.
Geppe NA et al. 2014. Promezhutochnyie itogi mnogotsentrovogo sravnitelnogo randomizirovannogo klinicheskogo issledovaniya. Antibiotiki i himioterapiya. 59; 7/8: 16—24.
Prohorov EV, Ostrovskiy IM, Akimochkina NA. 2007. Opyit ispolzovaniya i otsenka effektivnosti preparata Milistan ot kashlya pri ostroy bronhopnevmonii u detey. Zdorove rebenka. 4(7). http://www.mif-ua.com/archive/article/630.
Ovcharenko LS, Vertegel AA, Andrienko TG et al. 2007. Ratsionalnaya mukotropnaya terapiya ostrogo obstruktivnogo bronhita u detey. Novosti meditsinyi i farmatsii. 15(221). http://www.mif-ua.com/archive/article/2984.
Samsyigina GA. 2015. Kak lechit kashel u detey? Consilium medicum: Pediatriya. 1: 37—41.
Samsyigina GA. 2015. Hronicheskiy kashel v detskom vozdaste. Pediatriya. 94; 4: 163-170.
Yulish EI, Chernyisheva OE. 2013. Differentsirovannyiy podhod k lecheniyu kashlya u detey. Zdorove rebenka. 1(44): 22—25.
Yulish EI. 2012. Ratsionalnaya mukoliticheskaya terapiya v komplekse lecheniya bronholegochnyih zabolevaniy v detskom vozdaste. Zdorove rebenka. 8(43).
Paleari D, Rossi GA, Nicolini G, Olivieri D. 2011. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin Drug Discov. 6(11): 1203— 14. http://dx.doi.org/10.1517/17460441.2011.629646. Epub 2011 Oct 25.
Huang J, Xu J, Tian L, Zhong L. 2014. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol. Biochimie. 97: 92—103. http://dx.doi.org/10.1016/j.biochi.2013.09.024. Epub 2013 Oct 5.
Birring SS. 2011. Controversies in the evaluation and management of chronic cough. Am J Respir Crit Care Med. 183(6): 708—15. Medline. http://dx.doi.org/10.1164/rccm.201007-1017CI; PMid:21148722
Cataldi M, Sblendorio V, Leo A, Piazza O. 2014, Aug. Pulm Pharmacol Ther. 28(2): 98—108. http://dx.doi.org/10.1016/j.pupt.2013.11.002. Epub 2013 Nov 16.
Chalumeau M, Duijvestijn YCM. 2013. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Published Online: 31 MAY 2013. Assessed as up-to-date: 6 MAR 2013. http://dx.doi.org/10.1002/14651858.CD003124.pub4.
Chung KF. 2011. Chronic 'cough hypersensitivity syndrome': a more precise label for chronic cough. Pulm Pharmacol Ther. 24(3): 267—71. Medline. http://dx.doi.org/10.1016/j.pupt.2011.01.012; PMid:21292019
Alsubaiea H, Al-Shamranib A, Alharbic AS, Alhaiderd S. 2015. Clinical practice guidelines: Approach to cough in children: The official statement endorsed by the Saudi Pediatric Pulmonology Association (SPPA). International Journal of Pediatrics and Adolescent Medicine. 2; Issue 1: 38-43. http://dx.doi.org/10.1016/j.ijpam.2015.03.001
Wang S, Huang D, Ma Q, Chen X. 2014. Does ambroxol confer a protective effect on the lungs in patients under-going cardiac surgery or having lung resection? Interact Cardiovasc Thorac Surg. 18(6): 830—4. http://dx.doi.org/10.1093/icvts/ivu061.
Gibson PG, Ryan NM. 2011. Cough pharmacotherapy: current and future status. Expert Opin Pharmacother. 12(11): 1745—55. http://dx.doi.org/10.1517/14656566.2011.576249; PMid:21524236
Gupta PR. 2014. Ambroxol hydrochloride in the management of idiopathic pulmonary fibrosis: Clinical trials are the need of the hour. Lung India. 31(1): 43—6. http://dx.doi.org/10.4103/0970-2113.125899.
Gupta PR. 2010. Ambroxol — Resurgence of an old molecule as an anti-in-flammatory agent in chronic obstructive airway diseases. Lung India. 27(2): 46—8. http://dx.doi.org/10.4103/0970-2113.63603.
Wu X, Li S, Zhang J et al. 2014. Meta-analysis of high doses of ambroxol treatment for acute lung injury/acute respiratory distress syndrome based on randomized controlled trials. J Clin Pharmacol. 54(11): 1199—206. http://dx.doi.org/10.1002/jcph.389. Epub 2014 Sep 7.
Wilkinson M, Sugumar K, Milan SJ et al. 2014. Mucolytics for bronchiectasis. Published Online: 2 MAY 2014. Assessed as up-to-date: 19 JUN 2013. http://dx.doi.org/10.1002/14651858.CD001289.pub2.
Roomans GM, Johannesson М. 2013. The effect of ambroxol on chloride transport, CFTR and ENaC in cystic fibrosis airway epithelial cells. Cell Biol Int. 37(11): 1149—56. http://dx.doi.org/10.1002/cbin.10146. Epub 2013 Jul 23.
Zhou Y, Sun S, Liu H, Cui L, Chang X, Sun Z. 2014. Pharmazie. 69(11): 842—9. PMid:25985582
Cataldi M, Sblendorio V, Leo A, Piazza O. 2014. Biofilm-dependent airway infections: a role for ambroxol? Pulm Pharmacol Ther. 28(2): 98—108. http://dx.doi.org/10.1016/j.pupt.2013.11.002. Epub 2013 Nov 16.
